Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta
- •Wiek 18-75 lat
- •Rozpoznanie raka piersi bez receptorów hormonalnych (stadium II lub III)
- •Zakwalifikowana do leczenia przednowotworowego chemioterapią i immunoterapią (pembrolizumab)
✗ Disqualifies
- •Niemożność zrozumienia lub wyrażenia zgody na udział w badaniu
- •Niezukończenie co najmniej 2 z zaplanowanych cykli immunoterapii lub co najmniej 50% zaplanowanych cykli chemioterapii
- •Przyjmowanie codziennie co najmniej 10 mg kortyzonu lub równoważnika
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- March 19, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Centro Hospitalar Vila Nova de Gaia/Espinho
Vila Nova de Gaia, Portugal
Trial contact
Alexandra P. Guedes, Medical Oncologist M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.